Essen BioScience, Inc. Appoints Jim Ryder As Global Head Of Sales

Essen BioScience, Inc. ("Essen" or the Company), a leading provider of critical analytical instrumentation, software, reagents and services used in cell-based life science research, is pleased to announce that Jim Ryder will join the leadership team as Essen's new Global Head of Sales. 

Suggested Articles

The filing moves Deciphera closer to establishing ripretinib as an option for patients failed by drugs from Bayer, Novartis and Pfizer.

Charles River Labs is stumping up $380 million in cash to buy out cell therapy biomaterials producer HemaCare.

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.